Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.81 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.81 |
| ▸ | KCNH1 | O95259 | 4/20 | 0.81 |
| ▸ | APP | P05067 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17699499 | 0.93 | BACE1 (0.81) | BACE1BACE2KCNH1APPCYP3A4 | |
| SCHEMBL17699479 | 0.90 | BACE1 (1.00) | BACE1BACE2KCNH1APPCYP3A4 | |
| SCHEMBL16312277 | 0.88 | BACE1 (0.74) | BACE1BACE2KCNH1APPCYP3A4 | |
| SCHEMBL12524580 | 0.88 | BACE1 (0.80) | BACE1BACE2KCNH1APPCYP3A4 | |
| SCHEMBL16312251 | 0.88 | BACE1 (0.80) | BACE1BACE2KCNH1APPCYP3A4 | |
| SCHEMBL17699481 | 0.85 | BACE1 (0.70) | BACE1BACE2KCNH1APPKCNH2 | |
| SCHEMBL16312280 | 0.84 | BACE1 (1.00) | BACE1BACE2KCNH1APPCYP3A4 | |
| SCHEMBL20677607 | 0.84 | BACE1 (1.00) | BACE1BACE2KCNH1APPCYP3A4 | |
| SCHEMBL10175536 | 0.84 | BACE1 (1.00) | BACE1BACE2KCNH1APPCYP3A4 | |
| SCHEMBL14876661 | 0.83 | BACE1 (1.00) | BACE1BACE2APPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580433-B2 | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-20160115170-A1 | 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115170-A1 | 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885KCNH1 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.